Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Open Minds on Avandia? A Defining Challenge for the New Regulatory Climate

This article was originally published in RPM Report

Executive Summary

The run-up to FDA's re-review of Avandia is becoming highly charged. There is a lot riding on the outcome of the agency's decision on how to deal with the diabetes therapy. Here are a number of considerations to think about going into FDA's advisory committee meeting.

You may also be interested in...

IoM Will Address Ethics in Safety Studies Prior To Avandia Advisory Committees

FDA is acting to create political and scientific cover for the second public review of Avandia safety issues in mid-July. A former top staffer to House Energy & Commerce Chairman Waxman is doing an internal study of agency post-marketing safety procedures to assure Capitol Hill that FDA takes the issue seriously; an IoM workshop is convening in early June to prepare a preliminary review on the ethical issues with post-market safety studies.

The Avandia Re-Review: Three Scenarios

The Avandia advisory committee is a volatile event for GSK and the overall drug safety climate. The best and worst cases for the sponsor are not necessarily aligned with the best results for the industry overall. A look at three possible scenarios.

Broken RECORD: New Themes, Same Old Story for Avandia

Rosa DeLauro came to an Institute of Medicine meeting on regulatory science to praise FDA’s new leadership and to take credit for increasing its resources. But she also trashed the agency’s handling of Avandia. It isn’t clear that science has anything to do with that debate, but resolving it looks like a critical test for the agency and its new leadership this summer.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts